ArticleFrontiers in immunology2026
Integrated genomic and immunophenotypic profiling reveals monoclonal origin, smoking-driven evolution and heterogeneous microenvironment in pulmonary adenosquamous carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary adenosquamous carcinoma (ASC) is a rare, aggressive subtype of non-small cell lung cancer (NSCLC), characterized by both adenocarcinoma (ACC) and squamous cell carcinoma (SCCC) components. Due to its rarity, the clonal origin, evolutionary drivers, and tumor microenvironment (TME) of ASC remain poorly understood. Methods: We conducted clinical and prognostic analyses on 76 ASC patients. Nine patients with available tissues underwent microdissection to isolate matched ACC and SCCC regions, which were then analyzed using whole-exome sequencing (WES), copy-number analysis, phylogenetic reconstruction, and multiplex immunofluorescence (mIF) for immune profiling. Results: Multivariate Cox regression identified the histological subtype of the ACC component as an independent prognostic factor, with solid and micropapillary subtypes associated with the poorest overall survival. WES revealed frequent mutations in TP53 (56%), EGFR (33%), MET (33%), and PIK3CA (22%) across tumor regions. Shared truncal mutations and copy-number alterations between ACC and SCCC regions suggest a common monoclonal origin. Smokers had a significantly higher tumor mutational and neoantigen load than non-smokers, with greater overlap in mutations between ACC and SCCC. Phylogenetic analysis showed distinct evolutionary patterns: smokers' tumors displayed smoking-related and APOBEC mutational signatures, while non-smokers had aging-related signatures. mIF analysis revealed significantly higher immune cell infiltration (CD8 Conclusion: Our findings support a monoclonal origin for ASC, with smoking influencing divergent evolutionary trajectories and immune microenvironment characteristics between ACC and SCCC. These insights provide a molecular framework for personalized ASC therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.